TriLink Opens GMP Enzyme Manufacturing Facility, Ships First Commercial Batch to Streamline RNA Therapeutics Supply Chain
Key Insights
TriLink opened a new GMP enzyme manufacturing facility in Jupiter, Florida, designed to provide coordinated, single-source supply of critical IVT raw materials for RNA therapeutics developers.
The facility shipped its first commercial GMP enzyme batch in June 2026, with its flagship CleanScribe™ RNA Polymerase (search) reducing dsRNA formation by up to 85% compared to wild-type T7 polymerases.
The integrated offering combines GMP CleanScribe™, NTPs, CleanCap® (search) analogs, and ModTail™ (search) technology to reduce vendor complexity and accelerate development from IND-enabling studies through commercial launch.
TriLink BioTechnologies (search), part of Maravai LifeSciences (NASDAQ: MRVI), announced the opening of its new GMP enzyme manufacturing facility in Jupiter, Florida, marking a significant step toward simplifying the supply chain for RNA therapeutics developers. The facility, purpose-built for GMP enzyme manufacturing, is designed to provide a coordinated, single-source package of critical in vitro transcription (IVT) raw materials — enzymes, nucleotides, cap analogs, and tail technology — from early research through commercial production.
The launch addresses a persistent challenge in the RNA therapeutics field: developers have historically sourced critical raw materials from multiple vendors with disparate quality systems, timelines, and points of contact. "Managing different quality systems, timelines, and supply processes can slow development and create manufacturing risk," the company stated. TriLink's integrated approach aims to compress this complexity into a single, accountable partner relationship.
The facility is already operational and supporting customer programs. TriLink successfully shipped its first commercial GMP enzyme batch in June 2026, demonstrating the site's operational readiness and ability to provide commercial-scale supply to RNA therapeutics developers worldwide.
CleanScribe™ RNA Polymerase (search): Reducing dsRNA at the Source
The facility's flagship product is GMP CleanScribe™ RNA Polymerase (search), an engineered enzyme that reduces double-stranded RNA (dsRNA) formation by up to 85% compared to standard wild-type T7 RNA polymerases. This performance has been demonstrated across both internal and customer studies.
dsRNA represents a critical quality attribute in therapeutic mRNA manufacturing. Its accumulation drives purification complexity, depresses final RNA purity, and increases immunogenicity risk in vivo. By controlling dsRNA at the synthesis step, CleanScribe™ is designed to translate directly into downstream process efficiency and product quality.
An Integrated IVT Raw Materials Solution
TriLink is now offering a coordinated supply of GMP-grade IVT raw materials that includes GMP CleanScribe™ RNA Polymerase (search) Mix, GMP NTPs (nucleoside triphosphates), GMP CleanCap® (search) analogs — described as the industry-standard co-transcriptional capping reagents — and GMP ModTail™ (search) technology, designed to enhance mRNA stability and in vivo protein expression.
The integrated offering is intended to reduce vendor complexity, simplify tech transfer, and ensure material consistency across the development lifecycle, from IND-enabling studies through BLA submission and commercial launch.
"As RNA-based therapeutics move into later-stage clinical development and commercial production, reliable access to manufacturing materials becomes increasingly important," the company noted. "Enzyme performance variability, regulatory gaps in supplier quality systems, and multi-vendor logistics create compounding delays at precisely the stages when speed matters most."
Chad Decker, SVP Global Sales at TriLink BioTechnologies (search), emphasized the strategic value: "RNA therapeutics developers need reliable supply partners that can support them from early research through commercial manufacturing. By combining enzyme manufacturing capabilities with TriLink's existing RNA technologies, we help customers simplify sourcing, reduce supply chain complexity, and accelerate scale-up with greater confidence."
Global IP Strengthens with New China Patent
In a separate but related development, TriLink announced on July 20, 2026, that it had been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The patent covers TriLink's full suite of CleanCap® (search) capping analogs, including its latest M6 analog.
The allowed claims are directed to co-transcriptional RNA synthesis methods utilizing either trimer or tetramer capping structures. CleanCap® (search) technology is now patented across major world markets including the United States, the European Union, Australia, Japan, Korea, Hong Kong, Canada, and China.
"We are committed to defending our intellectual property rights, and this new patent represents an important tool in support of those efforts," said Bernd Brust, Chief Executive Officer of Maravai LifeSciences. "Maintaining strong intellectual property coverage in every major jurisdiction is central to our strategy."
Chanfeng Zhao, Chief Scientific Officer of TriLink BioTechnologies (search), added: "CleanCap® (search) offers significant advantages for mRNA programs. This patent reflects the depth of innovation our team has brought to mRNA manufacturing."
The technology enables co-transcriptional production of mRNAs containing the major natural cap structures found in humans, representing an improvement over legacy capping methods such as enzymatic capping and ARCA. CleanCap® (search) technology has been used in commercially approved COVID-19 (search) mRNA and saRNA vaccines and underpins drug development programs across mRNA therapeutics, oncology, infectious diseases, rare diseases, and cell and gene therapies.
The Jupiter facility features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.